Granite Bio
Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis.
$30M Series A ·
Led by Novartis Venture Fund · Source: fundraisingfox.com
Funding history ↓Signals
About Granite Bio
Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | $30M | fundraisingfox.com |
Timeline
- Website created
Founders and team
- MMMatthias Mack Founder
PL
Patrick Loustau President and CEO
Investors
FForbion Capital Partners
NNovartis Venture Fundlead investor
SSanofi Ventures
VVersant Ventureslead investor
Companies like Granite Bio
CCalluna Pharma$81M Series A · Jan 2024
CCamp4Series B+ · Jul 2022AAnaveon$120M Series B+ · Dec 2021
CCelea Therapeutics$180M Series A · Jul 2026
MMirador Therapeutics$250M Series B+ · Jan 2026
VVandria$30.7M Series A · Aug 2024
Other companies backed by Novartis Venture Fund
KKynexis$112.57M Series A · Aug 2026
FFore Biotherapeutics$67.4M Series B+ · Jul 2026
FFlare Therapeutics$85M Series B+ · Jun 2026
MMediar Therapeutics$76M Series B+ · Jan 2026
FFoRx Therapeutics$50M Series A · Dec 2025
NNRG Therapeutics$67M Series B+ · Sep 2025
Novartis Venture Fund portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/granite-bio (get a free API key).